从缺氧诱导因子-1α表达的变化探讨平喘Ⅰ号治疗支气管哮喘模型小鼠的作用机制研究OA

Objective To observe the changes and effects of the traditional Chinese medicine Anti-Asthma Formula Ⅰ on the expression of Hypoxia-Inducible Factor-1α(HIF-1α)in lung tissue of bronchial asthma mice,and to explore its mechanism in treating bronchial asthma.Methods Seventy-two 4-6 week-old mice were ran-domly divided into a normal control group,a model control group,a budesonide treatment group,an Anti-Asthma Formula Ⅰ low-dose group,an Anti-Asthma Formula Ⅰ medium-dose group,and an Anti-Asthma FormulaⅠ high-dose group,with 12 mice in each group.A model was established using intraperitoneal injection of ovalbu-min(OVA)and aerosol inhalation.Interventions were then administered with normal saline,budesonide aerosol solution,and three doses(low,medium,high)of Anti-Asthma Formula Ⅰ.After 3 weeks,lung tissue from asth-matic mice was obtained.Pathological sections were observed,and image analysis software was used to measure bronchial wall thickness(Wat)and airway smooth muscle thickness(Wam).Realtime quantitative polymerase chain reaction(Realtime-PCR)was employed to detect HIF-1α mRNA expression,and Western blotting was used to detect HIF-1α protein expression.Results In the normal control group,mouse bronchial lumens were smooth without occlusion,lung tissue showed intact structure,alveolar structure was clearly visible,and there were no inflammatory or edematous reactions.Compared with the normal control group,the model group exhibited narrowed bronchial lumens with some showing significant occlusion,inflammatory cell aggregation,damaged al-veolar morphology,and even edema-like changes within alveoli.After treatment,all Anti-Asthma Formula Ⅰ dose groups and the budesonide treatment group showed alleviated inflammatory reactions in lung tissue,and bron-chial lumen obstruction improved compared to the model group.Compared with the normal control group,Wat and Wam in the model control group were significantly increased,with a statistically significant difference be-tween the two groups(P＜0.01).All treatment groups were significantly lower than the model control group,with statistically significant differences(P＜0.01 or P＜0.05).The Anti-Asthma Formula Ⅰ high-dose group was signifi-cantly lower than the budesonide treatment group and the Anti-Asthma Formula Ⅰ medium-and low-dose groups,with statistically significant differences(P＜0.05),while there was no statistically significant difference between the Anti-Asthma Formula Ⅰ medium-and low-dose groups and the budesonide treatment group(P＞0.05).Com-pared with the normal control group,HIF-1α mRNA and protein expression levels in the model control group were significantly increased,with statistically significant differences between the two groups(P＜0.01).All treat-ment groups were significantly lower than the model control group,with statistically significant differences(P＜0.01 or P＜0.05).The Anti-Asthma Formula Ⅰ high-dose group was significantly lower than the budesonide treat-ment group and the Anti-Asthma Formula Ⅰ medium-and low-dose groups,with statistically significant differ-ences(P＜0.05),while there was no statistically significant difference between the Anti-Asthma Formula Ⅰmedium-and low-dose groups and the budesonide treatment group(P＞0.05).Conclusion HIF-1α plays an im-portant role in asthmatic airway remodeling.Anti-Asthma Formula Ⅰ can inhibit airway inflammation and remodel-ing and improve asthma symptoms by down-regulating HIF-1α expression.The high dose of Anti-Asthma FormulaⅠ is superior to budesonide in inhibiting HIF-1α expression and improving airway remodeling,showing potential clinical application value.